Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
Follow ABOS
Acumen Pharmaceuticals, Inc. (ABOS) EV/Sales
As of 16 October 2026, Acumen Pharmaceuticals, Inc. (ABOS) trades at a EV/Sales of 30.3×. Over the past ten years it has ranged from −79.8× (March 2022) to 269× (October 2021); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | −41.9× | — |
| FY2019 | −41.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | −41.9× | — |
| Sep 2020 | −41.9× | — |
| Jun 2020 | −41.9× | — |
| Mar 2020 | −41.9× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −73.2× |
| VYGR Voyager Therapeutics, Inc. compare | 0.0× |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | 1.5× |
| NRXP NRx Pharmaceuticals, Inc. compare | 22.6× |
| ABOS Acumen Pharmaceuticals, Inc. | 30.3× |
| HUMA Humacyte, Inc. compare | 40.3× |
| ARMP Armata Pharmaceuticals, Inc. compare | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)